ESSA Pharma Faces Class Action Lawsuit Over Alleged Securities Fraud

Multiple law firms have announced a class action lawsuit against ESSA Pharma Inc. for alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024. The complaints assert that ESSA misrepresented the efficacy of its drug masofaniten when combined with enzalutamide, and failed to disclose that the treatment was less effective for prostate cancer than claimed. Investors are encouraged to join the lawsuit before the March 25, 2025, deadline to potentially recover losses without incurring out-of-pocket fees. Law firms like Bronstein, Gewirtz & Grossman, and Levi & Korsinsky have outlined the necessary steps for investors to participate, emphasizing that the lawsuit aims to hold ESSA accountable for misleading statements. Rosen Law Firm also reminds investors of the importance of selecting experienced legal counsel for representation in this case. The lawsuit highlights significant concerns over ESSA's clinical and regulatory prospects, impacting investor trust.